Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Enthusiasm following Benlysta's approval has died down, and there remains a considerable need for effective biologic therapies
With considerable remaining unmet needs for effective biologic therapies, companies developing pipeline candidates for systemic lupus erythematosus (SLE) should consider lessons from Benlysta (belimumab; GlaxoSmithKline) in order to maximize their future commercial potential. As the only biologic to have been approved for SLE in over 50 years, Benlysta is considered the benchmark drug, and key opinion leaders note that new agents in development must demonstrate equal or superior efficacy before they will achieve equivalent uptake with rheumatologists in the US and five major EU markets (France, Germany, Italy, Spain, and the UK). Although the approval of Benlysta was met with widespread enthusiasm, in daily practice only a moderate number of patients fit the criteria for its use. Indeed, the drug is mostly used for maintenance therapy. Furthermore, skepticism still exists, fueled by mixed efficacy and results in practice. Nevertheless, Benlysta has faced little competition as other therapies have so far failed to match its success in Phase III.
Following very promising Phase IIb results, anifrolumab (AstraZeneca) has been propelled to the forefront of SLE drug development. AstraZeneca has invested in two large-scale Phase III trials, and if anifrolumab demonstrates similar efficacy in these trials, the company will be able to benefit from a wide open SLE market, with minimal competition in its way. However, numerous promising candidates have previously failed to succeed in Phase III, including Anthera Pharmaceuticals’ blisibimod and Merck KGaA’s atacicept, both of which failed to meet the primary endpoint in their Phase III trials, putting further development of both drugs in jeopardy. As a result, success for anifrolumab is far from guaranteed in this difficult market, until additional data become available.
Datamonitor Healthcare’s SLE marketed and pipeline analysis compares the clinical and commercial attractiveness of marketed and pipeline candidates, providing an assessment of future product positioning and competitiveness in the marketplace.
Request a Demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
Trialtrove is the go-to resource for clinical trial research. Easily track your competitors' clinical R&D activity with expert insights and continually monitored trials.
Biomedtracker provides real-time analysis of major market-moving events in the pharma and biotech industries. With catalyst tracking and expert insights, Biomedtracker helps you stay on top of breaking events, the drugs pipeline, upcoming milestones, companies, and deals – and their impact on the markets you care about.
Looking for more products Product Finder
